Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 6, 2003, Pages 1556-1564

  Goff, Barbara A ^a,b   Thompson, Tove ^a   Greer, Benjamin E ^a   Jacobs, Andrew ^b   Storer, Barry ^c   Peters III, William ^b  

^a Dept of Obstetrics and Gynecology ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Doxorubicin; Gemcitabine; Ovarian cancer; Peritoneal cancer; Platinum resistant

Indexed keywords

DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; BLADDER DISEASE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEALTH SURVEY; HEMOPTYSIS; HUMAN; HYPOCALCEMIA; INFECTION; INFLUENZA; LIVER TOXICITY; LUNG TOXICITY; METABOLIC DISORDER; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENT DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

EID: 0038338604     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.398     Document Type: Conference Paper

References (28)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;16:1070.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999;49:8-31.
3. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definition of the treated population. J Clin Oncol 1992;10:513-4.
4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
5. Lund B, Krisjansen PE, Hansen HH. Clinical and preclinical activity of 2′, 2′ diflurorodeoxy-cytidine (gemcitabine). Cancer Treat Rev 1993;19:45-55.
6. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′, 2′ difurorodeoxy-cytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
7. Lund B, Hansen OP, Neijt JP, Thellade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995;6(6 Suppl):61-2.
8. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1265-7.
9. Orlando M, Mandachain M. Gemcitabine in ovarian cancer. Semin Oncol 2001;28(3 Suppl):62-9.
10. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002;29 (1 Suppl):9-10.
11. Ozols RF. The current role of gemcitabine in ovarian cancer. Semin Oncol 2001;28(2 Suppl):18-24.
12. Thigpen T, Vance R, Puneky L, Hanson R. Chemotherapy in advance ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994;55:S97-107.
13. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1995;13:726-32.
14. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-32.
15. Perez-Manga G, Lluch A, Alba JA, Moreno-Nogueira M, Palomero J, Garcia-Conde D, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 2000;18:2545-52.
16. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
17. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
18. Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 1999;10(1 Suppl):21-7.
19. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
20. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
21. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
22. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 1999;22:450-2.
23. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 2000;19:405a.
24. Kudelka AP, Verschraegen CF, Edwards CL, Freedman RS, Plunket WK, Nicol S, et al. A preliminary report of a phase 2 study of gemcitabine in women with refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas [abstract]. Proc Am Soc Clin Oncol 1999;18:377a.
25. Du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the arbeitgemeinschaft gynakologische onkologie (AGO) ovarian cancer study group. Ann Oncol 2001;12:1115-20.
26. D'Agostino G, Ferrandina G, Garganese G, Salerno MG, Lorussso D, Farnetano MG, et al. Phase 1 study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 2002;62:110-4.
27. Pignata S, Varriale E, Casella G, Iodice F, De Placido G, Perrone F, et al. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Oncol 2000;11:613-6.
28. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91.